November 6, 2018 10:15 AM EST
News Briefing

Am­gen of­fers cash and mile­stones for Proven­tion to take the lead on a celi­ac drug; Aveo's PhI­II fails to im­press, shares slide

John Carroll

Editor & Founder

→ Lit­tle Proven­tion Bio has struck a deal to con­tin­ue the de­vel­op­ment work on Am­gen’s celi­ac drug, AMG 714. In ex­change for tak­ing over the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times